The objective of this study was to enhance the solubility of Methylprednisolone by choosing micronized form of drug and to enhance patient compliance by formulating it as dispersible tablets using quality by design (QbD) approach. Dispersible tablets of Methylprednisolone were developed by 2 3 factorial design. In this study independent variables were concentrations of MCC 102, CCS and Magnesium stearate and dependent variables were disintegration time, hardness and dissolution. The resulting data was fitted into Design Expert Software (Trial Version) and analyzed statistically using analysis of variance (ANOVA). The response surface plots were generated to determine the influence of concentration of MCC 102, CCS and magnesium stearate on responses. The tablets were prepared by direct compression method by choosing micronized form of drug and formulations were evaluated for the standard of dispersible tablets. Results showed that no significant drugpolymer interactions in FTIR studies. According to QbD suggestion the formulation O1 (Desirability-0.73) with MCC-38mg, CCS-3.5mg and magnesium stearate-2.5mg was formulated and evaluated. The disintegration time was found to be 69 seconds, hardness was found to be 64N and in vitro dissolution with in 30minutes. Optimized O1 formulation was within the limits of standards of dispersible tablets with increased water solubility and better patient compliance. Stability study on optimized O1 formulation showed that there is no significant changes during study period. Thus, O1 formulation was found to be stable. The study indicates that formulation of Methylprednisolone dispersible tablets by using QbD approach is a promising formulation development method.
INTRODUCTION
The aim of the present work was to develop dispersible tablets of Methylprednisolone using quality risk management tool of the Quality by Design (QbD) approach. Various formulation variables involved in the development of dispersible tablets was identified and it was optimized for minimum risk level using design of experiments (DoE) tool for efficient reduction in the risk assessment. This reduces the risks involved in the development of dispersible tablets and yields a good quality product. The study describes elements of the QbD for Methylprednisolone dispersible tablets include: Defining quality target product profile, identifying critical quality attributes, establishing design space, control strategy. Risk assessment was done before applying DoE. This will reduce the risks involved in the development of dispersible tablets and yields a good quality product. 1 A problem associated with Methylprednisolone is its poor dissolution characteristics with water solubility of about 120mcg/ml at 25
• C, which is a rate limiting step in the process of drug absorption. 2 For better patient compliance and increasing solubility micronisation and superdisintegrants addition turns out to be a best option. Thus dispersible tablets were formulated using direct compression technique by dry mixture of drug having a reduced particle size and to enhance disintegration superdisintegrants are added. 3 These agents are added to tablet formulations to promote the breakup of the tablet into smaller fragments in an aqueous environment thereby increasing the available surface area and promoting a more rapid release of the drug substance. 4, 5 Dispersible tablets as defined in European Pharmacopoeia are uncoated or film coated tablets intended to be dispersed in water before administration giving a homogeneous dispersion. Typically a dispersible tablet is dispersed in about 5-15ml of water (e.g. in a tablespoonful or a glass of water) and the resulting dispersion is administered to the patient. Dispersible tablets are required to disintegrate within 3min in water at [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] • C. Also the dispersion produced from a dispersible tablet should pass through a sieve screen with a nominal mesh aperture of 710 microns. 6 
MATERIALS AND METHOD

Materials:
Methylprednisolone (Micronized), Lactose Monohydrate (DCL 11), Microcrystalline cellulose (Avicel PH 102), Croscarmellose sodium, Aspartame, Trusil orange, Colloidal silicon dioxide and Magnesium stearate.
Method:
All the materials were individually dispensed and weighed. The sifted Methylprednisolone, Lactose spray dried DCL11, Microcrystalline cellulose PH (102), Croscarmellose Sodium, Colloidal silicon dioxide, Trusil orange, and Aspartame was loaded into polybag and mixed well for 10minutes. To the above blend sifted Magnesium stearate was added and mixed for 2mins. By direct compression the final lubricated blend is compressed in a 16 station compression machine (Cadmach) with 8.00mm punch size, round standard concave punch with plain on both the surface.
Experimental Design
Particle size:
Micronized drug is chosen to increase solubility of drug. Particle size of micronized drug Methylprednisolone was found to be 1817nm using particle analyzer (Malvern).
Compatibility study of drug and excipients using Fourier transform infrared spectroscopy:
The FTIR spectra were recorded for pure drug and the physical mixture of drug and excipients at the scanning range of 4000-400 cm-1 using FTIR spectrophotometer (Shimadzu, Japan). FT-IR spectra of Methylprednisolone showed sharp characteristic peaks (Fig. 1 ). All the above characteristic peaks appeared in the spectra of physical mixture of drug (Fig. 2) and excipients at same wave number indicating no interaction between the drug and excipients.
Initial risk assessment of the Formulation variable for development of Methylprednisolone dispersible tablets:
A risk assessment of the drug substance was performed to evaluate the impact of CQA in product development. The relative risk assessment ranking system was used during development and it was summarized in Table 1 . 7 Quality Target Product Profile (QTPP) element analysis of drug product:
The QTPP is "a prospective summary of the quality characteristics of a drug product that ideally will be achieved to ensure the desired quality, taking into account safety and efficacy of the drug product." [8, 9] The QTPP is an essential element of a QbD approach and forms the basis of design of the generic product. Table 2 summarizes an account of all the actual values and levels of independent variables. All other formulation variables were kept in\variant throughout the study. The resulting data was fitted into Design Expert Software (Trial Version) and analyzed statistically using analysis of variance (ANOVA).
The data was also subjected to response surface methodology to determine the influence of concentration of independent variable on responses.
Evaluation of Dispersible tablets:
To determine weight variation, twenty tablets were selected randomly from each formulation and were weighed individually using a digital balance (Essae). The individual weights were compared with the average weight for obtaining the weight variation. 12 Ten tablets from each formulation were selected randomly and their thickness was measured with a Vernier caliper (Mitutoyo). Hardness of the tablets was measured using a Hardness tester (Electrolab) and friability of a sample of twenty fast dissolving tablets was measured using a USP type-II Roche friabilator (Electrolab). Pre-weighed tablets were placed in a plastic chambered friabilator attached to a motor revolving at a speed of 25 rpm for 4 min. The tablets were then dusted, reweighed and percentage weight loss (friability) was calculated. In vitro dispersion time was determined by placing one tablet in a beaker containing 10 ml of water and time required for complete dispersion was measured as shown in Fig. 3 . Three tablets from each formulation were randomly selected and dispersion time was performed. 13 Uniformity of dispersion was determined by placing two tablets in 100ml of water and stirred gently until completely dispersed. 14 A smooth dispersion obtained should passes through sieve screen with nominal mesh aperture of 710µm (sieve no. 22). Dispersible tablets must disintegrate within 3min.
In vitro dissolution studies were performed in distilled water with volume of 900ml using USP apparatus Type -II (paddle) at temperature of 37±0.5
• C. 15 The dissolution profiles of F1 to F10 formulations are depicted in Fig. 4 .
Optimization of Methylprednisolone Dispersible Tablets Using 2 3 Factorial Design:
Response 1 -Disintegration time:
Contour plot in Fig. 5 shows that Magnesium stearate in the level of 2.5-3.5mg and Croscarmellose sodium in the level 2.0-3.5mg will gives good result on disintegration time. 3D Response surface plot in Fig. 6 shows that disintegration time increase with increase in the concentration of magnesium stearate and disintegration time decreases by increasing the concentration of CCS. From ANOVA in Table 5 the Model F-value of 26.05 implies the model is significant. There is only a 0.40% chance that a "Model F-Value" this large could occur due to noise. In this case A, B, C, BC are significant model terms.
Response 2 -Hardness:
Contour plot in Fig. 7 shows that magnesium stearate in the level of 2.0-4.0mg and Microcrystalline cellulose in the level 37.5-41mg will gives good result on hardness. 3D Response surface plot in Fig. 8 shows that hardness increase with increase in the concentration of microcrystalline cellulose and hardness decreases by increasing the concentration of magnesium stearate. From ANOVA in Table 6 the Model Fvalue of 729.35 implies the model is significant. There is only a 0.01% chance that a "Model F-Value" this large could occur due to noise. Values of "Prob > F" less than 0.0500 indicate model terms are significant. In this case A, C, AC are significant model terms. Values greater than 0.1000 indicate the model terms are not significant.
Response 3 -In vitro Dissolution:
Contour plot in Fig. 9 shows that magnesium stearate in the level of 2.0-4.0mg and croscarmellose sodium in the level 2.5-3.5mg will gives good result on dissolution. 3D Response surface plot in Fig. 10 shows that dissolution increase with increase in the concentration of croscarmellose sodium and dissolution decreases by increasing the concentration of magnesium stearate. From ANOVA in Table 7 the Model Fvalue of 165.95 implies the model is significant. There is only a 0.07% chance that a "Model F-Value" this large could occur due to noise. Values of "Prob > F" less than 0.0500 indicate model terms are significant. In this case A, B, C, AC, BC are significant model terms. Values greater than 0.1000 indicate the model terms are not significant.
Formulation and Evaluation of Optimized Formulation O1:
From the results of optimization study it was found that MCC in the concentration 37-41mg, CCS in concentration 2.5 -3.5mg and magnesium stearate in concentration 2.5 -3.5mg gives optimized product. So, Constrains are fixed as shown in Table 8 and according to QbD suggestion the formulation O1 (Desirability-0.73) with MCC-38mg, CCS-3.5mg and Magnesium stearate-2.5mg was formulated and evaluated for physical parameters and in vitro dissolution ( Table 9) .
Assay of optimized formulation O1: (By HPLC)
Mobile phase: 475:475:70:35:30 (butyl chloride: watersaturated butyl chloride: THF: Methanol: glacial acetic acid); Wave length: 254nm. Internal standard solution (ISS): 20mg of prednisolone was weighed and dissolved in a 3% v/v solution of glacial acetic acid in chloroform (0.2mg/ml of prednisolone). Reference solution 20mg of drug was weighed and dissolved in 100ml of ISS (0.2mg/ml of drug). Test solution: A quantity of powdered tablet containing 10mg of drug was weighed and 50.0ml of ISS was added. 10µl of blank, reference solution and test solution was injected and the peak of drug was measured. [16] Related substances of optimized formulation O1: (By HPLC) 
Release Kinetics of Optimized formulation O1:
The mechanism of release for the above formulations was determined by finding the R 2 value for each kinetic model like, zero-order, first-order, higuchi, korsmeyer-peppas and hixon.R 2 value of Higuchi model is very near to one for all most all the formulations than the R 2 values of other kinetic models. Thus, it can be said that the drug release follows higuchi release mechanism. Further the n value of Korsmeyer-Peppas model for the optimized formulation was 1.095. Therefore, the most probable mechanism of release was Super case II transport.
Stability study for optimized formulation O1:
In the present study, stability studies were carried out on optimized formulation under accelerated study at 40±2ºC and RH 75% condition for three months. The tablets were withdrawn at 1 st and 3 rd month and analyzed for physical characterization and drug release as shown in Table 10 .
RESULTS AND DISCUSSION
As the material was free flowing (angle of repose value <30" and Carrs index <15%), tablets obtained were of uniform weight (due to uniform die fill). All the formulated (F1 to F10) tablets passed weight variation test as the % weight variation was within the IP limits of ±7.5% of the weight. The prepared formulation complies with the weight variation test. The maximum thickness of the formulation was found to be 4.0mm. The minimum thickness of the formulation was found to be 3.2mm. The hardness of the tablet was found to be 44 -110N. The maximum friability of the formulation was found to be 0.96%. The minimum friability of the formulation was found to be 0.85%. The % friability was less than 1% in all the formulations ensuring that the tablets were mechanically stable. In vitro Disintegration time was found to be in the range 47 -147 sec. All the formulations passes the uniformity of dispersion test. Dispersion time was found to be in the range 25 -46sec for all the formulation. Among all the formulations F5, F6, F7 and F8 shows 100%
ISSN: 2250-1177
[232] CODEN (USA): JDDTAO drug release within 30minutes and all the formulations complies the in vitro dissolution test for dispersible tablets.
Based on CQA to ensure that the product meets its intended safety, efficacy, stability and performance microcrystalline cellulose, croscarmellose sodium and magnesium stearate were selected as independent variable and based on risk assessment study dissolution, disintegration time and hardness were selected as dependent variable for optimization study. From the results of optimization study it was found that MCC in the concentration 37-41mg, CCS in concentration 2.5 -3.5mg and magnesium stearate in concentration 2.5 -3.5mg gives optimized product. So, constrains are fixed from results of study.
According to QbD suggestion the formulation O1 (Desirability-0.73) with MCC-38mg, CCS-3.5mg and magnesium stearate-2.5mg was formulated and evaluated. The disintegration time was found to be 69 seconds, hardness was found to be 64N and in vitro dissolution with in 30minutes. Assay for optimized O1 formulation was found to be 102.25% and related substances of known and unknown impurities was found to be 0.04% and 0.02% respectively. Thus optimized O1 formulation was within the limits of standards of dispersible tablets with increased water solubility and better patient compliance.
Short-term stability studies of the above formulation indicated that there are no signicant changes in physical characterization and drug release at the end of 3 month period (P<0.05). Thus O1 formulation was found to be stable.
Thus formulation of Methylprednisolone dispersible tablets by selecting micronized form of drug for increasing water solubility will reduces the problem associated with selected drug. Present scenario of Methylprednisolone dispersible tablets will finds a greater advantage due to its flexible design, better patient compliance, masking bitter taste of drug, combines the advantages of conventional dosage form, cost effectiveness and use of QbD approach for minimizing the risks involved in the development of dispersible tablets will yields a good quality product when compared to other coventional forms. Ensures better design of products with fewer problems in manufacturing. It is a cost effective method to develop generic drug production. The product can be consistently produced without batch to batch variations. 
